

GSK2033

Catalog No: tcsc0029828



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1221277-90-2

Formula:

$C_{29}H_{28}F_3NO_5S_2$

Pathway:

Metabolic Enzyme/Protease

Target:

LXR

Purity / Grade:

>98%

Solubility:

DMSO : 30 mg/mL (50.70 mM; Need ultrasonic and warming)

Observed Molecular Weight:

591.66


Product Description

GSK2033 is a **LXR** antagonist with **pIC₅₀**s of 7 and 7.4 for **LXR α** or **LXR β** , respectively.

IC₅₀ & Target: pIC₅₀: 7 (LXR α), 7.4 (LXR β)^[1]

In Vitro: GSK2033 is a LXR antagonist with pIC₅₀s of 7 and 7.4 for LXR α or LXR β , respectively. GSK2033 dose-dependently suppresses basal transcription in full-length LXR α or full-length LXR β cotransfection assays with IC₅₀s of 17 nM and 9 nM, respectively. GSK2033 also effectively suppresses the transcription of an *ABCA1* driven luciferase reporter dose-dependently displaying IC₅₀s of 52 nM for LXR α and 10 nM for LXR β . GSK2033 also suppresses the expression of both of fatty acid synthase (*FASN*) and *SREBP1*^[2].

In Vivo: One month treatment of GSK2033 does not have significant effects on hepatic triglyceride levels. Plasma triglyceride levels are also unaffected by treatment with GSK2033^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!